Shares of Bioamber Inc (NYSE:BIOA) reached a new 52-week low on Tuesday . The company traded as low as $0.19 and last traded at $0.19, with a volume of 7037684 shares trading hands. The stock had previously closed at $0.38.

A number of analysts recently weighed in on the company. Zacks Investment Research upgraded Bioamber from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Bioamber in a report on Wednesday, November 8th. ValuEngine cut Bioamber from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, Cowen reaffirmed a “hold” rating and set a $1.00 price objective on shares of Bioamber in a report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the company’s stock. Bioamber presently has a consensus rating of “Hold” and an average target price of $6.50.

The firm has a market cap of $10.07, a price-to-earnings ratio of -0.28 and a beta of 2.52. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.08 and a quick ratio of 0.75.

Bioamber (NYSE:BIOA) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter. Bioamber had a negative return on equity of 48.72% and a negative net margin of 238.43%. analysts predict that Bioamber Inc will post -0.53 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of BIOA. Bank of New York Mellon Corp raised its holdings in Bioamber by 336.2% during the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 41,701 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Bioamber by 9.9% in the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after acquiring an additional 27,278 shares during the last quarter. FMR LLC raised its holdings in shares of Bioamber by 1.9% in the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Robecosam AG raised its holdings in shares of Bioamber by 82.9% in the third quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 670,000 shares during the last quarter. 29.97% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/02/06/bioamber-bioa-reaches-new-52-week-low-at-0-19.html.

Bioamber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.